Role of interferons in demyelinating disease

  • K. P. Johnson
Conference paper


Interferon beta lb (Betaseron®) was licensed by the U.S. Federal Food and Drug Administration in July 1993 as the first treatment to alter the natural history of multiple sclerosis (MS). The drug, injected subcutaneously every other day, reduced the frequency of relapses and the expansion of central white matter pathology as measured by MRI. Twelve previous interferon trials in MS, employing a variety of interferon preparations, doses and routes of administration, preceded this trial and provided the scientific foundation for its success. Beta interferon therapy probably inhibits gamma interferon to achieve its therapeutic effect. Future MS therapy may require combination treatment with multiple agents with complimentary immunologic effects.


Multiple Sclerosis Multiple Sclerosis Patient Cerebral Spinal Fluid Interferon Beta Multiple Sclerosis Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Basham TY, Merigan TC (1983) Recombinant interferon gamma increases HLA-DR synthesis and expression. J Immunol 130: 1492–1494PubMedGoogle Scholar
  2. Bornstein MB, Johnson KP (1992) Treatment of multiple sclerosis with copolymer I. In: Rudick RA, Goodkin DE (eds) Treatment of multiple sclerosis. Trial design, results and future perspectives. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  3. Dhib-Jalbut SS, McFarlin DE (1990) Immunology of multiple sclerosis. Ann Allerg 64: 433–444PubMedGoogle Scholar
  4. IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655–661Google Scholar
  5. Jacobs L, Salazar AM, et al (1987) Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis: results of a multicenter, double-blinded study. Arch Neurol 44: 589–595PubMedGoogle Scholar
  6. Johnson KP, Knobler RL, et al (1990) Recombinant human interferon beta treatment of relapsing-remitting multiple sclerosis: pilot study results. Neurology 40 [Suppl 1]: 261Google Scholar
  7. Knobler RL, Panitch HS, Braheny SL, et al (1984) Systemic alpha-interferon therapy of multiple sclerosis. Neurology 34: 1273–1279PubMedGoogle Scholar
  8. Noronha A, Toscas A, Jensen MA (1990) Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol 27: 207–210PubMedCrossRefGoogle Scholar
  9. Panitch HS (1992) Interferons in multiple sclerosis. A review of the evidence. Drugs 44 (6): 946–962PubMedCrossRefGoogle Scholar
  10. Panitch HS, Bever CT jr (1993) Clinical trials of interferons in multiple sclerosis. What have we learned? J Neuroimm 46: 155–164CrossRefGoogle Scholar
  11. Panitch HS, Hirsch RL, Schindler J, Johnson KP (1987) Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 37: 1097–1120PubMedGoogle Scholar
  12. Paty DW, Li DKB, et al (1993) Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 662–667PubMedGoogle Scholar
  13. Sharief MK, Hentges R (1991) Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med 325: 467–472PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1997

Authors and Affiliations

  • K. P. Johnson
    • 1
  1. 1.School of Medicine, Room N4 W46University of MarylandBaltimoreUSA

Personalised recommendations